Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | IL1RN | P18510 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30859067 | 1.00 | MAOA (0.55) | MAOAMAOBPRCPANPEPIL1RN | |
| Hydrochloric Acid SCHEMBL28967142 | 0.98 | MAOA (0.53) | MAOAMAOBPRCPANPEPIL1RN | |
| SCHEMBL27773304 | 0.87 | MAOB (0.48) | MAOAMAOBMAPKAPK2 | |
| SCHEMBL28299306 | 0.87 | MAOA (0.48) | MAOAMAOBPRCPANPEPIL1RN | |
| SCHEMBL28252708 | 0.87 | MAOB (0.48) | MAOAMAOBPRCPANPEPIL1RN | |
| SCHEMBL15391341 | 0.87 | MAOA (0.48) | MAOAMAOBPRCPANPEPIL1RN | |
| SCHEMBL20526412 | 0.85 | MAOA (0.47) | MAOAMAOBPRCPANPEPIL1RN | |
| SCHEMBL17482466 | 0.85 | MAOA (0.39) | MAOAMAOBPRCPANPEPIL1RN | |
| SCHEMBL2098553 | 0.84 | MAOA (0.46) | MAOAMAOBMAPKAPK2ADORA2AADORA1 | |
| SCHEMBL11572806 | 0.83 | MAOB (0.44) | MAOAMAOBMAPKAPK2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 879 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660057-B2 | Systems and methods for persistent ureter visualization | STRYKER CORPORATION (US) | 2023-05-30 | — | — | US | claimed |
| EP-3997710-A1 | SYSTEMS AND METHODS FOR PERSISTENT URETER VISUALIZATION | Stryker Corporation (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3861343-A1 | ULTRABRIGHT FLUORESCENT NANOCONSTRUCTS AS UNIVERSAL ENHANCERS | Washington University (US) | 2021-08-11 | — | — | EP | claimed |
| US-11077211-B2 | Compositions and methods for assessing gut function | MEDIBEACON INC. (US) | 2021-08-03 | — | — | US | claimed |
| CN-113167791-A | Ultrabright fluorescent nano-constructs as universal enhancers | 华盛顿大学 | 2021-07-23 | — | — | CN | claimed |
| US-11049906-B2 | Imaging device, manufacturing device, and manufacturing method | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2021-06-29 | — | — | US | claimed |
| CN-107078143-B | Imaging device, manufacturing device and manufacturing method | 索尼半导体解决方案公司 | 2021-06-15 | — | — | CN | claimed |
| CN-112717146-A | Compositions and methods for assessing gut function | 麦迪贝肯有限公司 | 2021-04-30 | — | — | CN | claimed |
| US-10967096-B2 | Tissue sealant compositions, vascular closure devices, and uses thereof | MEDIBEACON INC. (US) | 2021-04-06 | — | — | US | claimed |
| US-10960104-B2 | Tissue sealant compositions, vascular closure devices, and uses thereof | MEDIBEACON INC. (US) | 2021-03-30 | — | — | US | claimed |
| CN-101194380-A | Light-emitting element, method for manufacturing light-emitting element, electronic device, and electronic apparatus | SEIKO EPSON CORP (JP) | 2008-06-04 | — | — | CN | claimed |
| EP-1854489-A1 | Method of measuring physiological function | MALLINCKRODT, INC. (US) | 2007-11-14 | — | — | EP | claimed |
| WO-2007106142-A2 | PROCESS FOR USING OPTICAL AGENTS | MALLINCKRODT INC. (US) | 2007-09-20 | — | — | WO | claimed |
| EP-1642597-A2 | Method of measuring physiological function | MALLINCKRODT, INC. (US) | 2006-04-05 | — | — | EP | claimed |
| US-20040242902-A1 | Labeling Dna in automatic sequencing; bar codes; lipid solubility | APPLIED BIOSYSTEMS, INC. | 2004-12-02 | — | — | US | claimed |
| WO-2004101709-A1 | PHENYL XANTHENE DYES | APPLERA CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| EP-1154802-A1 | METHOD OF MEASURING PHYSIOLOGICAL FUNCTION | Mallinckrodt Inc. (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050093-A1 | METHOD OF MEASURING PHYSIOLOGICAL FUNCTION | MALLINCKRODT INC. (US) | 2000-08-31 | — | — | WO | claimed |
| CN-1039014-C | Novel modified oligodeoxynucleotide | SANKO CO LTD (JP) | 1998-07-08 | — | — | CN | claimed |
| CN-1098107-A | modified oligodeoxynucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1995-02-01 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077211-B2 | Compositions and methods for assessing gut function | FABP2, SLC10A2, SI | MAOA 1999/4885MAOB 1763/4885PRCP 1517/4885 |
| US-20040242902-A1 | Labeling Dna in automatic sequencing; bar codes; lipid solubility | IPO8, BCR, NR1H3 | MAOA 3531/4885MAOB 3074/4885PRCP 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.